Dawn Christine Maroney

ALHC President Maroney sells 177.1K shares at $20.83 (scheduled 10b5-1 plan); holds 922.3K post-sale amid weak fundamentals

President Dawn Christine Maroney sold 177,068 shares at $20.83 on 2026-07-15 as part of a pre-arranged 10b5-1 trading plan, reducing non-derivative holdings by 16.1% to 922,313 shares. The company's fundamentals remain challenged: annual revenue growth of 46.1% to $1.2B masks persistent unprofitability (negative full-year net income) and an elevated P/E of 200.30, while the stock has declined 20.3% from its 52-week high. Her prior five trades at ALHC show mixed outcomes (30-day returns ranging from -24.6% to +19.7%, 90-day from -21.1% to +13.0%), with no clear directional pattern. The scheduled nature of this sale via 10b5-1 plan removes discretionary intent as a signal; the trade reflects predetermined execution rather than a timing-driven conviction statement.

ALHC President sells 30,000 shares at $19.55 via pre-arranged 10b5-1 plan; post-transaction holdings 947.3K shares.

President Maroney executed a scheduled sale of 30,000 shares (30.0K shares) for $586,425.00 ($586.4K) via a pre-arranged 10b5-1 trading plan, reducing her holdings by 3.1% to 947.3K shares. The transaction occurred while ALHC trades at -17.1% from its 52-week high of $23.87, and notably, Maroney's prior trade at this ticker on 2026-04-15 registered a -24.6% return over 30 days, signaling adverse timing outcomes in her recent ALHC-specific activity. Against broader context, ALHC's full-year net income was negative and the company sports a P/E of 197.80 with revenue of $1.2B, reflecting a high-valuation, early-stage profitability profile. Since this sale is governed by a pre-arranged plan, the transaction lacks discretionary intent signals; however, the convergence of a negative full-year result, elevated valuation multiples, and the -24.6% 30-day loss on her prior same-ticker sale warrants attention to ALHC's operational trajectory.

President Maroney Dawn Christine sold 30,000 shares of ALHC at $20.87; stock +19.5% in 30 days post-sale despite her 80% well-timed sell rate cross-ticker.

Maroney sold 30,000 shares (-2.8% of pre-transaction holdings) at $20.87 on 2026-04-15, reducing her stake to 1,028,813 shares. Notably, the stock has risen 19.5% in the 30 days following this sale, departing from her cross-ticker track record where she has achieved a 80.00% well-timed sell rate with an average 90-day return of -7.1% after her sells. At the same ticker, her prior four measurable sells have shown positive 30-day returns (+19.7%, +20.6%, +17.3%, -12.0%), suggesting a pattern of selling before rallies rather than declines. The company remains unprofitable on a full-year basis despite 46.1% annual revenue growth, and the stock trades at a 40.23 P/E multiple, creating an asymmetric risk environment where insider sells into strength warrant attention.

ALHC: President Maroney sold 30,000 shares at $17.48 on 2026-03-16 via 10b5-1 plan ($524.4K)

Maroney Dawn Christine, President of Alignment Healthcare, sold 30,000 shares at $17.48 per share on 2026-03-16 through a pre-arranged 10b5-1 trading plan, reducing her holdings by 2.7% to 1,095,562 shares. Because this transaction is scheduled under a 10b5-1 plan rather than discretionary, it reflects a commitment made at an earlier date and does not represent a current market judgment. The transaction itself is routine in scale relative to her remaining position of 1.10M shares, indicating continued material insider ownership after the sale.

ALHC: President Maroney sells 30,000 shares at $20.63; stock down 8.5% in 30 days and down 13.5% from 52-week high.

Maroney Dawn Christine, President of Alignment Healthcare, sold 30,000 shares (30.0K shares) at $20.63 on 2026-02-17, reducing holdings from 1,027,015 shares to 997,015 shares (a -2.9% reduction). The stock has declined 8.5% over the past 30 days and is currently 13.5% below its 52-week high of $23.81, trading at $20.59. At ALHC specifically, Maroney's prior 5 trades include two recent sales (on 2026-01-15) that have shown significant near-term declines of -11.4% and -9.0% respectively, though outcomes at the 90-day mark remain unmeasurable for all five same-ticker trades. The company's full-year net income was negative despite robust revenue growth of 48.2%, and current profitability remains marginal at $3.7M on $993.7M quarterly revenue. The timing of this sale within a recent downtrend and following a series of prior sales at this ticker merits monitoring, though the modest 2.9% reduction in holdings suggests a measured disposition rather than a aggressive exit.

ALHC President sold 30,000 shares (30.0K shares) for $674,450.94 on 2026-01-15; 5th sell in 2 weeks

Maroney Dawn Christine (President) executed 2 separate sales totaling 30,000 shares for $674,450.94 at blended average price $22.48, proximate to the current price of $22.50 and the 52-week high. This transaction reduces her ALHC holdings by 2.8% to 1,027,015 shares. The notable context is the frequency pattern: SAME-TICKER HISTORY shows 5 prior sells in the past month (four clustered 2026-01-06 through 2026-01-02, and three in 2025-12-29 through 2025-12-15), with the earliest measurable outcome (2025-12-15 sale) showing a +8.7% 30-day return for the stock—indicating the insider's prior sells at this ticker have not preceded declines. The company recently reported FY net income as negative, though latest-quarter net income was $3.7M and revenue grew +48.2% YoY, suggesting a turnaround inflection. With the stock near its 52-week high and rising sharply (+9.5% in 30 days, +31.4% in 90 days), frequent insider sales at peak valuation merit monitoring for sustainability of the rebound.

ALHC President sold 328,152 shares for $6,871,050.10 via scheduled 10b5-1 plan on Jan 2-6, 2026

Maroney sold 328,152 shares (328.2K shares) across two separate transactions at $20.03 on 2026-01-02 and $21.33 on 2026-01-06, generating $6,871,050.10 total and reducing holdings from 1,385,167 shares to 1,057,015 shares. This disposition was part of a pre-arranged 10b5-1 trading plan, meaning the timing and volume were scheduled in advance rather than discretionary. The President retains 1,057,015 shares post-transaction, maintaining a substantial ongoing stake in the company. As a scheduled trade under Rule 10b5-1, this sale reflects a previously committed execution plan rather than a near-term conviction signal about the stock.

ALHC President Maroney sells 130,000 shares (130.0K shares) for $2.6M as stock hits 52-week high of $20.11

Maroney Dawn Christine, President of Alignment Healthcare, executed two separate sales on 2025-12-12 and 2025-12-15, totaling 130,000 shares for $2,601,110.86 at a blended average price of $20.01, reducing her holdings by 7.2% to 1,667,237 shares. The sales occurred as ALHC's stock price reached its 52-week high of $20.11, up 21.7% over the preceding 30 days and 21.6% over 90 days. At this ticker, Maroney's prior five sales showed mixed execution: three sales in September 2025 were followed by strong 90-day gains of 17.0%, 14.0%, and 18.4% respectively, while a April 2025 sale preceded a 30.0% decline over 90 days, and a March 2025 sale was followed by a -9.4% 90-day return. The company reported quarterly revenue of $993,695,000.00 with annual revenue growth of 48.2%, though it remains unprofitable on a full-year basis with negative net income despite recent quarterly profitability of $3,729,000.00. The timing of this sale at a 52-week price high warrants observation against the backdrop of the company's strong top-line growth but ongoing profitability challenges.

ALHC President Maroney Dawn Christine sold 107,223 shares at $16.42 under pre-arranged 10b5-1 plan

Maroney Dawn Christine, President of Alignment Healthcare, sold 107,223 shares at $16.42 on 2025-09-10 for total proceeds of $1,760,204.93, reducing her holdings from 1,904,460 shares to 1,797,237 shares (a net decline of -5.6%). This transaction executed under a pre-arranged 10b5-1 trading plan, meaning the sale was scheduled in advance rather than discretionary. As a scheduled disposition, this transaction does not reflect real-time decision-making by the insider in response to current market conditions or company developments. The sale represents routine portfolio rebalancing under a predetermined schedule and lacks the timing signal that would accompany a discretionary trade.

ALHC President Maroney sold 230,000 shares at $19.10 (4/14); pre-arranged 10b5-1 plan

Maroney Dawn Christine, President of Alignment Healthcare, sold 230,000 shares at $19.10 on 2025-04-14, reducing holdings from 2,362,899 shares to 2,132,899 shares. This sale was executed under a pre-arranged 10b5-1 trading plan, meaning it was scheduled rather than discretionary. The president retains 2,132,899 shares post-transaction, maintaining a substantial ownership stake despite the sale. As a 10b5-1 plan execution, the timing of this transaction reflects a predetermined schedule rather than any tactical decision by the insider.